An integrin receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ATN-161 (trifluoroacetate salt)

Item No. 34056

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-aspartamide, monotrifluoroacetate salt
CAS Number
904763-27-5
Synonyms
  • Ac-PHSCN-NH2
  • PHSCN Peptide
Molecular Formula
C23H35N9O8S • CF3COOH
Formula Weight
711.7
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 1 mg/ml
SMILES
OC(C(F)(F)F)=O.NC(C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CN=CN1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O)=O
InChi Code
InChI=1S/C23H35N9O8S.C2HF3O2/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35;3-2(4,5)1(6)7/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38);(H,6,7)/t13-,14-,15-,16-,17-;/m0./s1
InChi Key
MCVJOWHOEOLJGI-LQCLSJOXSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $128

    Add

    10 mg

    $219

    Add

    25 mg

    $377

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    ATN-161 is a peptide derived from fibronectin and an integrin αVβ3 and αVβ5 antagonist.1 It binds to αVβ3 and αVβ5 receptors (Kds = 0.69 and 1 µM, respectively) in MDA-MB-231 breast cancer cells, as well as inhibits the interaction between αVβ5 and human angiotensin-converting enzyme 2 (ACE2) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a concentration-dependent manner in cell-free assays.1,2 ATN-161 reduces viral titers in Vero E6 cells infected with SARS-CoV-2 (EC50 = 3.16 µM).2 It inhibits VEGF-induced migration and capillary tube formation of primary human choroidal endothelial cells when used at a concentration of 0.1 µM.3 ATN-161 (1 mg/kg) reduces tumor growth and metastasis in an MDA-MB-231 mouse xenograft model and infarct volume and edema in a mouse model of ischemic stroke induced by middle cerebral artery occlusion (MCAO).1,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Khalili, P., Arakelian, A., Chen, G., et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5(9), 2271-2280 (2006).

    2. Beddingfield, B.J., Iwanaga, N., Chapagain, P.P., et al. The integrin binding peptide, ATN-161, as a novel therapy for SARS-CoV-2 infection. JACC Basic Transl. Sci. 6(1), 1-8 (2021).

    3. Wang, W., Wang, F., Lu, F., et al. The antiangiogenic effects of integrin α5β1 inhibitor (ATN-161) in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 52(10), 7213-7220 (2011).

    4. Edwards, D.N., Salmeron, K., Lukins, D.E., et al. Integrin α5β1 inhibition by ATN-161 reduces neuroinflammation and is neuroprotective in ischemic stroke. J. Cereb. Blood Flow Metab. 40(8), 1695-1708 (2020).